Probiotics improving intestinal barrier function
Official title: Effects of DL-endopeptidase Produced by Probiotics on Human Intestinal NOD2 Ligands and Related Functions
Run by Zhujiang Hospital · NCT06716047 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing whether a special probiotic can help improve gut health by repairing the intestinal barrier in people with digestive issues.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Zhujiang Hospital Academic / other |
| Locations | 1 site (Canton, Guangzhou) |
| Trial ID | NCT06716047 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals interested in improving their gut health and who meet the inclusion criteria.
✕Probably not a fit
Patients with severe digestive symptoms or chronic diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial investigates the effects of a specific probiotic that produces DL-endopeptidase on human intestinal health. Participants will take the probiotic orally for a designated period, during which blood and stool samples will be collected, along with questionnaires to assess efficacy and safety. The study aims to evaluate how this probiotic can repair the intestinal barrier and regulate enteritis, contributing to overall gut health.
Why it matters
Potential benefit: If successful, this could enhance gut health and improve intestinal barrier function for patients.
How similar studies have gone: Other studies have shown promising results with probiotics in gut health, suggesting potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * tend to participate the trial Exclusion Criteria: * severe digestive symptoms, such as severe vomiting, hematochezia, bloody or tarry stool within one month before intervention; antibiotics or laxatives or probiotics or intestinal antiulcer agent within one month before intervention; previous or current treatment for any diseases or illnesses such as gastrointestinal disease (gastric ulcers, Crohn's, celiac, ulcerative colitis, etc.); other chronic diseases (diabetes, kidney disease, etc.) or immunecompromising diseases or conditions (HIV/AIDS, autoimmune, hepatitis, cancer, transplant patient etc.); pregnant or lactating.
Where it's running
-
Industrial Avenue 253, canton
Canton, Guangzhou, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Metabolic Health Trajectories in Overweight Chinese Adults
This observational study follows overweight and obese Chinese adults to see how metabolic health changes over five years and whether people stay healthy, develop diabetes, or have complications.
-
Theta-burst temporal interference stimulation to improve awareness in people with disorders of consciousness
This study will test whether theta-burst patterned temporal interference stimulation (tTIs) can help adults with recent disorders of consciousness (vegetative or minimally conscious) show more signs of awareness.
-
Probiotic LR607 with neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer
The team will try giving adults with resectable stage IB–IIIC non-small cell lung cancer a daily probiotic (Lactobacillus rhamnosus LR607) alongside neoadjuvant chemoimmunotherapy to see if it improves tumor response and is safe.
-
Low- versus high-dose nafamostat for anticoagulation during CRRT in ICU patients
This study tests whether starting nafamostat at 50 mg/h rather than 20 mg/h keeps CRRT filters from clotting longer in adult ICU patients on continuous renal replacement therapy.
-
Anrikefen vs Nalfurafine for sleep quality in kidney disease patients with itching
A randomized, open-label study tests whether the injectable Anrikefen improves sleep better than the oral nalfurafine in adults on hemodialysis with CKD-associated itching.
-
Luspatercept to treat anemia after donor stem cell transplant
This trial will try luspatercept in people with acute leukemia who have anemia after an allogeneic (donor) stem cell transplant to see if it raises hemoglobin without transfusions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.